YALE COMPREHENSIVE CANCER CENTER

我们请求继续支持耶鲁癌症中心， 获得NCI指定的综合癌症中心的认可。主要 该中心的重点是在分子医学和应用的 新的生物学进入诊所，带来预防方面的进展， 癌症的诊断和治疗。在此应用程序中，我们请求支持 14个研究项目，其中5个是新的重组项目 专注于特定的疾病或科学突破， 和临床研究工作（癌症遗传学，遗传治疗/医疗 肿瘤学和血液学，干细胞生物学和移植，乳腺癌 研究淋巴瘤研究），以及14个共享资源，其中6个是新的 自上次应用以来（生物统计学、医学信息学、快速病例 基因治疗人类应用，遗传咨询和 基因靶向服务）。此外，一项关于前列腺的新研究计划 癌症已经建立和支持YCC，和三个前 研究方案和一项共享资源已逐步取消。以来 最近一次申请，由于大力征聘， 几个YCC计划，以及领导和行政部门的变化 中心的结构。我们请求支持高级领导层， 项目主管的水平，反映他们的实际时间承诺， 该中心及其方案，并为足够的行政人员， 确保YCC的持续顺利运作及其作为一个 综合癌症中心YCC拥有强大的研究基础， 5400万美元的同行评审资金，其中1390万美元 美元来自NCI赠款，不包括CCSG。自上次 提交的重大变更也导致了更实质性的临床 为数据管理和生物统计学提供强有力支持的试验计划 以及建立临床试验网络（耶鲁肿瘤学 网络或YON），这将使YCC成员能够灵活地测试 他们的研究成果对实际应用的影响， 在YCC集水区的癌症患者，包括不应得的 在YON机构的影响范围内的人口。

We request continued support for the Yale Cancer Center and the continued recognition as an NCI designated comprehensive cancer center. The major focus of the Center is in molecular medicine and the application of the new biology into the clinics to bring about progress in the prevention, diagnosis and treatment of cancer. In this application we request support for 14 research programs, five of which are new restructured programs focusing on specific diseases or scientific thrusts that bridge laboratory and clinical research efforts (Cancer Genetics, Genetic Therapy/Medical Oncology and Hematology, Stem Cell Biology and Transplant, Breast Cancer Research Lymphoma Research), and 14 shared resources, six of which are new since the last application (Biostatistics, Medical Informatics, Rapid Case Ascertainment, Genetic Therapy Human Applications, Genetic Counseling and Gene Targeting Service). In addition a new research program on prostate cancer has been established and supported by YCC, and three former research programs and one shared resource have been phases out. Since the last application a strong recruiting effort has led to restaffing of several YCC programs, and changes in leadership and administrative structure of the Center. We request support for the senior leadership, program directors at a level that reflects their actual time commitment to the center and its programs and for sufficient administrative staff to ensure the continued smooth functioning of the YCC and its evolution as a comprehensive cancer center. The YCC has a robust research base of a total of $54 million dollars in peer reviewed funding of which $13.9 million dollars comes from NCI grants exclusive of the CCSG. Since the last submission major changes have also resulted in a more substantial clinical trials program with strong support for data management and Biostatistics and the establishment of a clinical trials network (The Yale Oncology Network or YON), that will allow the YCC members the flexibility to test the impact of their research results on the practical applications for people with cancer in the YCC catchment area including the undeserved populations in the sphere of influence of YON institutions.